NCT06077656View on ClinicalTrials.gov

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

October 25, 2023

Primary Completion Date

May 24, 2024

Study Completion Date

May 24, 2024

Conditions
Pneumococcal Vaccines
Interventions
BIOLOGICAL

IVT PCV-25 Formulation A

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and low dose adjuvant

BIOLOGICAL

IVT PCV-25 Formulation B

25 valent pneumococcal conjugate vaccine containing low dose polysaccharide and high dose adjuvant

BIOLOGICAL

IVT PCV-25 Formulation C

25 valent pneumococcal conjugate vaccine containing high dose polysaccharide and high dose adjuvant

BIOLOGICAL

PCV 20

20 valent pneumococcal conjugate vaccine

Trial Locations (4)

V5Z 4H4

Inventprise Clinical Site, Vancouver

B3K 6R8

Inventprise Clinical Site, Halifax

B2N IL2

Inventprise Clinical Site, Truro

G1W 4R4

Inventprise Clinical Site, Saint-Louis

Sponsors

Lead Sponsor

Inventprise Inc.
All Listed Sponsors
collaborator

Canadian Center for Vaccinology

OTHER

collaborator

Vaccine Evaluation Center, Canada

OTHER

collaborator

PATH

OTHER

lead

Inventprise Inc.

INDUSTRY

NCT06077656 - Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine | Biotech Hunter | Biotech Hunter